India Globalization Capital, Inc. (NYSEAMERICAN: IGC) is running for the top once again this morning, following up on the 300%+ gains the stock experienced yesterday. The gains come after the company received the green light from the FDA to move forward with a clinical trial centered around the idea that cannabis can be used as an option in the treatment of Alzheimer’s disease.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
IGC Wins Big On FDA Approval
Yesterday, India Globalization Capital told investors that the FDA has approved its request to move forward with a Phase 1 clinical trial. The trial will assess the company’s proprietary cannabinoid compound as a potential treatment option for dementia in patients with Alzheimer’s disease.
Read more at Alpha Stock News!